Clinical Trials Browser

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Colorectal Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Ras-mutated Metastatic Colorectal Cancer

Advanced Gynecological Malignancies

Brain Neoplasms

Colorectal Neoplasms

Lung Diseases, Interstitial

Colorectal Neoplasms

Rectal Neoplasms Malignant

Ovarian Neoplasms

Colorectal Neoplasms

Medulloblastoma

Colorectal Neoplasms

Ovarian Neoplasms, Recurrence

Colorectal Neoplasms

Colorectal Neoplasms

Advanced Solid Tumor

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Appendiceal Neoplasms, Colorectal Neoplasms

Lung Neoplasms

Colonic Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Breast Cancer With Brain Metastasis

Ovarian Neoplasms

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

Colorectal Neoplasms

Advanced Ovarian Cancer

Colorectal Neoplasms

Extensive Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Metastatic Colorectal Cancer With Left-sided Primary Tumor

Neutropenia, Colorectal Neoplasms

Stomach Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Colorectal Neoplasms

Clinical Trials

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

SYS6090 Combination Therapy in Advanced Lung Cancer

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

QLS5132 Combination Therapy in Advanced Solid Tumors

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

COLIBRI-GI

PNOC044

ARIEL-ENGIC

TROY

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

REFISH

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

THUMB

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

ANGELICA

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

ONTOP

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

QL1706

IMMUNOLIFE2

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

BETWEEN

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC